@article{e90e796da4644be9a921945c2a9df272,
title = "Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes",
abstract = "Aims/hypothesis. The short-term efficacy, safety and tolerability of rosiglitazone were compared with placebo in patients with Type II (non- insulin-dependent) diabetes mellitus in a dose-ranging study. Methods. After a 2-week placebo run-in phase, 303 patients were randomly assigned to 8 weeks of treatment with twice-daily placebo or 2, 4 or 6 mg of rosiglitazone. Results. All rosiglitazone doses significantly reduced fasting plasma glucose compared with baseline. All rosiglitazone treatment groups showed significantly reduced peak postprandial glucose concentrations compared with baseline (p < 0.001) and with placebo (p < 0.0001) and reduced postprandial glucose excursion, without an increase in the area under the postprandial insulin concentration-time curve. Rosiglitazone at 4 and 6 mg twice daily prevented the increase in HbA(1c) observed in the placebo group. C peptide and serum insulin concentrations were significantly reduced from baseline in all rosiglitazone treatment groups. In all rosiglitazone treatment groups, non-esterified fatty acids decreased significantly (p < 0.0001) and triglycerides did not change. Although total LDL and HDL cholesterol increased significantly in the rosiglitazone treatment groups, total cholesterol/HDL ratios did not change significantly. The proportion of patients with one or more adverse event was similar in all four treatment groups. No patient showed evidence of hepatotoxicity. Conclusion/interpretation. Rosiglitazone given twice daily significantly reduced fasting and postprandial glucose concentrations, C peptide, insulin and non-esterified fatty acids in Type II diabetic patients. The glucose- lowering effect of the 4-mg twice-daily dose of rosiglitazone was similar to that of 6-mg twice daily, suggesting that 4 mg twice daily should be the maximum clinical dose.",
keywords = "Efficacy, Insulin resistance, Non- esterified fatty acids, Rosiglitazone, Thiazolidinedione, Type II diabetes",
author = "Philip Raskin and Rappaport, {E. B.} and Cole, {S. T.} and Y. Yan and R. Patwardhan and Freed, {M. I.}",
note = "Funding Information: B Amin, Midtown Family Medicine, Columbia, SC; L Blonde, Alton Ochsner Medical Foundation, New Orleans, La; T Brodie, Vista Medical Research, Mesa, AZ; H Cathcart, Northside Internal Medicine, Spokane, Wash; PK Champion, Kelsey-Seybold Clinic – Medical Center, Houston, Tex; E Conrad, Lake Medical Clinic, Lake Oswego, Or; M Farmer, Clinical Studies, Florida, St. Petersburg, Fla; J Gabriel, North Hills Medical Research, North Richland Hills, Tex; G Gewirtz, Joslin Center for Diabetes at Saint Barnabas, West Orange, NJ; WJ Henry, MeDQuest, Greer, SC; JR Herbst, Hill Top Research, Portland, Or; KS Hershon, North Shore Diabetes & Endocrine Associates, New Hyde Park, NY; S Hsi, Albuquerque, NM; J Isaacsohn, Metabolic and Atherosclerosis Research Center, Cincinnati, Oh; D Iverson, Cascade Physicians, Portland, Or; C Kilo, Kilo Clinical Research, St. Louis, Mo; A Koff, GHSD Parkview Hospital, Philadelphia, Pa; A Lewin, National Research Institute, Los Angeles, Calif; A Licata, The Cleveland Clinic Foundation, Cleveland, Oh; J Mersey, Mersey Clinical Research, Baltimore, Md; W Mullican, MediSphere Medical Research Center, Evansville, Ind; L Mulmed, Abbott North-western Diabetes Center, Minneapolis, Minn; JV Murray, Hill Top Research, St. Petersburg, Fla; PA Orlander, University of Texas Health Science Center, Houston, Tex; RG Paolino, Health Center, Bensalem, Pa; M Patel, Taunton Health Clinic, Taunton, Ma; P Raskin, University of Texas Southwestern Medical Center at Dallas, Dallas, Tex; G Redmond, Center for Health Studies, Cleveland, Oh; J Reusch, VA Medical Center, Section of Endocrinology, 111H University Hospital, Denver, Colo; S Rosenblatt, The Irvine Clinical Research Center, Ir-vine, Calif; C Stuart, University of Texas Medical Branch at Galveston, Galveston, Tex; D Sugimoto, Cedar-Crosse Research Center, Chicago, Ill; R Weinstein, Diablo Clinical Research, Walnut Creek, Calif; T Williams, Clinical Studies, Arizona, Peoria, Ariz; J Wilson, Advanced Research Management, LP (ARM), Seattle, Wash; K Wingert, Community Medical Providers, Clovis, Calif",
year = "2000",
doi = "10.1007/s001250050045",
language = "English (US)",
volume = "43",
pages = "278--284",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "3",
}